Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lisata Therapeutics, Inc. - Common Stock (NQ: LSTA )

2.510 -0.110 (-4.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
Via Benzinga
Exposures Fossil Fuels
Nasdaq Surges 1.5%; Procter & Gamble Posts Upbeat Earnings
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For Lisata Therapeutics
Via Benzinga
US Stocks Higher; Netflix Profit Beats Estimates
Via Benzinga
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Netflix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Lisata Therapeutics to Present at the 2025 Sequire Investor Summit
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial
Phase 1b/2a open-label trial in the U.S. of certepetide in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon and appendiceal cancers 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging
License provides Lisata’s innovative certepetide targeting agent for use with Kuva’s NanoMark™ MR imaging platform to advance non-invasive, high-precision cancer diagnostics 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Dave Mazzo, CEO of Lisata Therapeutics Inc. (NASDAQ: LSTA), to Present at NobleCon20
Via Investor Brand Network
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Study will investigate the benefits of combining Lisata's novel product candidate, certepetide, with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in preclinical tumor models 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis
Strategic partnership explores therapeutic effect of Lisata’s novel cyclic peptide product candidate, certepetide, in combination with bevacizumab 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial
Study arm initiated based upon enthusiasm and at the request of investigators who participated in first-line cholangiocarcinoma cohort 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
LSTA Stock Earnings: Lisata Therapeutics Beats EPS for Q2 2024
LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024
From Lisata Therapeutics, Inc.
Via GlobeNewswire
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via GlobeNewswire
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing... 
Via Benzinga
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
From Lisata Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS